Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesBeginning Cash BalanceCash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

InMed Pharmaceuticals (INM) Capital Expenditures: 2021-2024

  • InMed Pharmaceuticals' Capital Expenditures was N/A to $2 in Q1 2024 from the same period last year, while for Mar 2024 it was -$179,074, marking a year-over-year change of. This contributed to the annual value of $9,293 for FY2024, which is 94.19% down from last year.
  • Latest data reveals that InMed Pharmaceuticals reported Capital Expenditures of $2 as of Q1 2024, which was down 99.99% from $31,816 recorded in Q2 2023.
  • In the past 5 years, InMed Pharmaceuticals' Capital Expenditures ranged from a high of $250,000 in Q3 2021 and a low of -$214,445 during Q4 2021.
  • In the last 3 years, InMed Pharmaceuticals' Capital Expenditures had a median value of $3,553 in 2022 and averaged $11,790.